Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 18;3(5):620-631.
doi: 10.1002/hep4.1334. eCollection 2019 May.

Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention

Affiliations

Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention

Kelly L Hayward et al. Hepatol Commun. .

Abstract

People with decompensated cirrhosis are often prescribed a complex regimen of therapeutic and prophylactic medications. In other chronic diseases, polypharmacy increases the risk of medication misadventure and medication-related problems (MRPs), with associated increased morbidity, mortality, and health care costs. This study examined MRPs in a cohort of ambulatory patients with a history of decompensated cirrhosis who were enrolled in a randomized controlled trial of a pharmacist-led, patient-oriented medication education intervention and assessed the association between MRPs and patient outcomes. A total of 375 MRPs were identified among 57 intervention patients (median, 6.0; interquartile range, 3.5-8.0 per patient; maximum 17). Nonadherence (31.5%) and indication issues (29.1%) were the most prevalent MRP types. The risk of potential harm associated with MRPs was low in 18.9% of instances, medium in 33.1%, and high in 48.0%, as categorized by a clinician panel using a risk matrix tool. Patients had a greater incidence rate of high-risk MRPs if they had a higher Child-Pugh score (incidence rate ratio [IRR], 1.31; 95% confidence interval [CI], 1.09-1.56); greater comorbidity burden (IRR, 1.15; 95% CI, 1.02-1.29); and were taking more medications (IRR, 1.12; 95% CI, 1.04-1.22). A total of 221 MRPs (58.9%) were resolved following pharmacist intervention. A greater proportion of high-risk MRPs were resolved compared to those of low and medium risk (68.9% versus 49.7%; P < 0.001). During the 12-month follow-up period, intervention patients had a lower incidence rate of unplanned admissions compared to usual care (IRR, 0.52; 95% CI, 0.30-0.92). Conclusion: High-risk MRPs are prevalent among adults with decompensated cirrhosis. Pharmacist intervention facilitated identification and resolution of high-risk MRPs and was associated with reduced incidence rate of unplanned hospital admissions in this group.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of patient recruitment and follow‐up timelines. Reasons for missed contact among intervention patients included overseas travel (3 patients), current inpatient (5 patients), transfer of care to another facility (1 patient), and failure to attend appointment/answer phone for other reasons (9 patients).
Figure 2
Figure 2
Proportion of unplanned admissions among intervention and usual care patients during the follow‐up period.

Comment in

References

    1. Guan R, Lui HF. Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol 2011;2011:918017. - PMC - PubMed
    1. El‐Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A, et al. Basline factors associated with improvements in decompensated cirrhosis after direct‐acting antiviral therapy for hepatitis C virus infection. Gastroenterology 2018;154:2111‐2121. - PubMed
    1. Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol 2012;107:247‐252. - PMC - PubMed
    1. Agrawal K, Kumar P, Markert R, Agrawal S. Risk factors for 30‐day readmissions of individuals with decompensated cirrhosis. South Med J 2015;108:682‐687. - PubMed
    1. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533‐543. - PubMed